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ABSTRACT
Background. The rapid spread of azithromycin resistance in sexually transmitted
Mycoplasma genitalium infections is a growing concern. It is not yet clear to what degree
macrolide resistance inM. genitalium results from the emergence of de novomutations
or the transmission of resistant strains.
Methods. We developed a compartmental transmission model to investigate the
contribution of de novo macrolide resistance mutations to the spread of antimicrobial-
resistant M. genitalium. We fitted the model to resistance data from France, Denmark
and Sweden, estimated the time point of azithromycin introduction and the rates
at which infected individuals receive treatment, and projected the future spread of
resistance.
Results. The high probability of de novo resistance in M. genitalium accelerates the
early spread of antimicrobial resistance. The relative contribution of de novo resistance
subsequently decreases, and the spread of resistant infections in France, Denmark and
Sweden is now mainly driven by transmitted resistance. If treatment with single-dose
azithromycin continues at current rates, macrolide-resistant M. genitalium infections
will reach 25% (95% confidence interval, CI [9–30]%) in France, 84% (95% CI [36–
98]%) in Denmark and 62% (95% CI [48–76]%) in Sweden by 2025.
Conclusions. Blind treatment of urethritis with single-dose azithromycin continues
to select for the spread of macrolide resistant M. genitalium. Clinical management
strategies forM. genitalium should limit the unnecessary use of macrolides.
Subjects Computational Biology, Mathematical Biology, Epidemiology, Infectious Diseases,
Public Health
Keywords Mycoplasma genitalium, Mathematical model, Antibiotic resistance, Sexually
transmitted infection
INTRODUCTION
Macrolide-resistant Mycoplasma genitalium poses a considerable problem for clinical
practice and public health, with more than 40% of detected infections being resistant in
several countries (Gesink et al., 2012; Pond et al., 2014; Salado-Rasmussen & Jensen, 2014;
Murray et al., 2017). M. genitalium is a sexually transmitted bacterium, which is often
asymptomatic and, untreated, persists for more than a year (Smieszek & White, 2016; Cina
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et al., 2019). The prevalence ofM. genitalium in the general population aged 16 to 44 years
has been estimated to be 1.3% (95% confidence interval, CI [1.0–1.8]%) and 3.9% (95%
CI [2.2–6.7]%) in countries with higher and lower levels of development (Baumann et al.,
2018), and is similar in women and men. Like Chlamydia trachomatis,M. genitalium causes
non-gonococcal urethritis (NGU) in men (Taylor-Robinson & Jensen, 2011) and lower and
upper genital tract disease in women (Wiesenfeld & Manhart, 2017).
M. genitalium was first isolated in 1980 from two men with NGU (Tully et al., 1981),
but it has fastidious growth requirements, is slow-growing and difficult to culture (Taylor-
Robinson & Jensen, 2011), hampering the progress of clinical research. Reliable detection,
first by polymerase chain reaction and subsequently other nucleic acid amplification tests
(NAATs), was not possible until the early 1990s, (Gaydos, 2017). Most currently used
diagnostic tests do not detect resistance mutations, but commercial assays that can provide
information on macrolide resistance have become available (Unemo & Jensen, 2017). In
most clinical settings, however, NAATs for M. genitalium diagnosis are still not available.
The clinical syndrome of NGU is therefore often treated empirically, with a single 1g dose
of azithromycin recommended for first line treatment in many countries since the late
1990s (Bradshaw, Jensen & Waites, 2017).
Macrolide resistance inM. genitalium results from a single nucleotidemutation in region
V of the 23S rRNA gene, most commonly A2058G or A2059G. Jensen et al. (2008) identified
these mutations in Australian and Swedish men, with NGU caused byM. genitalium, who
experienced clinical treatment failure with 1g azithromycin. The men carried a wild-type
organism before treatment, but post-treatment specimens contained mutations in the
23S rRNA gene that conferred macrolide resistance. Since then, other investigators have
detected macrolide resistance mutations de novo (also known as acquired, induced
or selected) in M. genitalium (Ito et al., 2011; Twin et al., 2012; Anagrius, Loré & Jensen,
2013; Bissessor et al., 2015; Couldwell et al., 2013; Walker et al., 2013; Falk, Enger & Jensen,
2015; Read et al., 2017), and a meta-analysis of studies published up to 2016 estimated a
12.0% (95% CI [7.1–16.9]%) probability of de novo resistance after treatment with 1g
of azithromycin (Horner et al., 2018). Once acquired, untreated resistant strains can be
transmitted to new sexual partners.
Recommendations for future research on M. genitalium prioritize the need for more
effective and safe antimicrobials (Martin, Manhart & Workowski, 2017). It is important
to understand the degree to which treatment failure in M. genitalium results from the
emergence of de novo resistance mutations or the transmission of resistant strains because
the type of resistance will influence future treatment strategies. The objective of this
study was to investigate the role of de novo and transmitted resistance in the spread of
azithromycin-resistantM. genitalium.
METHODS
We developed a mathematical model of M. genitalium transmission and fitted it to
epidemiological data about time trends in macrolide resistance. We define ‘de novo’ as a
change from a drug-sensitive infection before treatment to a drug-resistant infection after
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treatment, either by selection of one or a few pre-existing resistant mutants in an otherwise
drug-sensitive bacterial population or due to a novel resistance mutation evolving during
drug exposure. Mathematical modeling and parameter inference were conduced in the R
software environment for statistical computing (R Core Team, 2016). All code files for the
transmission model are available on GitHub (https://github.com/calthaus/MG-resistance).
Epidemiological data
We searched Pubmed up toMay 4, 2018.We used themedical subject headingsMycoplasma
genitalium AND drug resistance, bacterial and found 67 publications. From these, two
authors independently selected six studies for three countries that met the following
criteria: country with multiple studies that reported on M. genitalium and macrolide
resistance mutations, data for more than three years from the same region or the entire
country, and use of different strategies to test and treat M. genitalium. For each country,
we recorded the testing strategy and treatment regimen, year in which azithromycin was
introduced for M. genitalium treatment, numbers of specimens with positive results for
M. genitalium and the number with macrolide resistance mutations. We contacted study
authors for additional information. For each year, we calculated the proportion (with 95%
CI) of azithromycin-resistantM. genitalium.
Transmission model
We developed a deterministic, population-based compartmental model that describes
the spread of drug resistant M. genitalium (Fig. 1, Table 1). The model consists of
four compartments: susceptibles (S), people infected with a drug-sensitive strain of
M. genitalium (IS), and people infected with a drug-resistant strain of M. genitalium that
was either acquired during treatment (IA) or transmitted (IT ). Assuming a homogenous
population without demography, the transmission dynamics can be described by the
following set of ordinary differential equations (ODEs):
dS
dt
=−βS(IS+ IA+ IT )+γ (IS+ IA+ IT )+ (1−µ)τ IS, (1)
dIS
dt
=βSIS−γ IS−τ IS, (2)
dIA
dt
=µτ IS−γ IA, (3)
dIT
dt
=βS(IA+ IT )−γ IT , (4)
where β is the transmission rate, which is assumed to be the same for both strains of M.
genitalium. Both types of infections can clear naturally at rate γ . Patients receive treatment
at rate τ . The treatment rate is defined as all occasions of treatment with a single 1g dose
of azithromycin in a person infected withM. genitalium, either with or without symptoms.
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Figure 1 Structure of the transmissionmodel forMycoplasma genitalium.
Full-size DOI: 10.7717/peerj.8913/fig-1
Table 1 Parameters of the transmissionmodel forMycoplasma genitalium. CI: confidence intervals.
Parameter Description Value (95% CI) Reference or comment
β Transmission rate 0.816 person−1 y−1 Calibrated to prevalence
γ Natural clearance rate 0.8 y−1 Smieszek & White (2016)
τ Treatment rate of 0.04 y−1 (0.03–0.04 y−1) Model estimate: France
infected individuals 0.13 y−1 (0.05–0.34 y−1) Model estimate: Denmark
0.14 y−1 (0.11–0.18 y−1) Model estimate: Sweden
µ Probability of de novo 12% Horner et al. (2018)
resistance during treatment
µdenotes the probability of de novo resistance emergence during treatment. The de novo
emergence of resistance also implies that the treatment failed. We used the point estimate
of the probability of de novo resistance emergence of 12% from Horner et al. (2018). For
simplicity, we assumed that resistant infections only clear naturally, with no second-line
treatment.
In the transmission model, drug-sensitive (IS) and drug-resistant (IA and IT )
M. genitalium strains compete for the same resource, i.e., the susceptible hosts (S). The rate
at which the resistant strain replaces the sensitive strain can be expressed by the difference
in their net growth rates (1φ) (Bonhoeffer, Lipsitch & Levin, 1997; Fingerhuth et al., 2016):
1φ =φA+T −φS
=
dIA
dt + dITdt
IA+ IT −
dIS
dt
IS
=
(
βS−γ + µτ IS
IA+ IT
)
− (βS−γ −τ ) (5)
= τ
(
1+ µIS
IA+ IT
)
= τ
(
1+ µ(1−p)
p
)
,
where p denotes the proportion of resistant infections among all infections. Note that
1φ does not depend on the transmission rate β or the natural clearance rate γ , i.e., is
unaffected by the overall prevalence ofM. genitalium.
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Model parameters
We set the natural clearance rate (γ ) of M. genitalium to 0.8 y−1 (Smieszek & White,
2016). We calibrated the transmission rate β to 0.816 person−1 y−1, which results in an
equilibrium prevalence of 2% in the absence of treatment and is consistent with estimates
of the prevalence of M. genitalium in sexually active adults in high-income countries
(Baumann et al., 2018). The values for the transmission rate and the natural clearance
rate, and correspondingly the initial prevalence, do not govern the relative growth rate of
the drug-resistant proportion (1φ), so they do not influence the relative prevalence of
resistant infections or themodel fits and parameter estimates.We did not find any published
evidence of the effect of macrolide resistance on the fitness ofM. genitalium strains, so we
assumed that any fitness reduction is negligible and that resistant and wild-type strains have
the same infectivity. The probability of emergence of de novo resistance during treatment
(µ) was set to 12%, as reported in the meta-analysis by Horner et al. (2018).
Model fitting and simulations
We fitted the transmission model to country-specific resistance data to obtain maximum
likelihood estimates of the treatment rate of infected people, τ , and the time point T
for the introduction of azithromycin. Given a model-predicted proportion of resistant
strains pi= IA(i)+IT (i)IS(i)+IA(i)+IT (i) in year i (Table 2), the binomial log-likelihood to find ki resistant
samples in Ni tested individuals is
L(τ ,T )=
∑(
log
Ni
ki
+ki logpi+ (Ni−ki)log(1−pi)
)
. (6)
Simulations start at timeT with 98%uninfected people, 2%peoplewith drug-susceptible
infections and no drug-resistant infections. We used log-transformed parameters for the
estimation and stipulated that the lower and upper limits of T could not be before 1990
or after the time point when resistance was first observed. We derived simulation-based
95% CIs for the model curve from 10,000 bootstrap samples from the multivariate normal
distribution of the two parameters using the R packagemvtnorm. We used the ode function
from the package deSolve to solve the ODEs, and themle2 function from the package bbmle
using the Nelder–Mead method for log-likelihood optimization.
To investigate the influence of the level of de novo resistance emergence on the rapid rise
in the proportion of resistant infections, we simulated two alternative scenarios. In these
scenarios, we kept the model-derived maximum likelihood estimates of τ and T but set
the probability of de novo resistance emergence to lower values (µ= 1% and µ= 0.1%).
RESULTS
Description of the data
We included six studies that provided data about the proportion of azithromycin-resistant
M. genitalium infections over time and the management of M. genitalium infection in
France (Chrisment et al., 2012; Touati et al., 2014; Le Roy et al., 2016; Le Roy et al., 2017),
Denmark (Salado-Rasmussen & Jensen, 2014), and Sweden (Anagrius, Loré & Jensen,
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Table 2 Characteristics of studies with time trend data about azithromycin-resistantM. genitalium infections. rRNA, ribosomal ribonucleic acid; MG,M. genitalium;
RT-PCR, real-time PCR.
Reference Study year Setting Study Method of Number of Number of samples Comments
or period population detection MG positive with mutations in
samples tested 23S rRNA gene
Chrisment et al. (2012) 2003 Pellegrin Hospital, Retrospective analysis of RT-PCR and 1 0 Only 4 specimens
2004 Bordeaux, France; MG-positive specimens from sequencing 10 0 from Paris clinic
2005 Saint-Louis Hospital, sexually transmitted disease 6 0
2006 Paris France clinics and general practice 10 1
2007 clinics 15 2
2008 13 2
2009 21 3
2010 39 5
Touati et al. (2014) 2011 Pellegrin Hospital, Retrospective analysis of RT-PCR and 69 10
2012 Bordeaux, France; MG-positive specimens high-resolution 65 9
melt analysis
Le Roy et al. (2016) 2013 Bordeaux University Retrospective analysis of RT-PCR and 112 19
2014 Hospital, Bordeaux, MG-positive specimens high-resolution 109 19
France melt analysis
Le Roy et al. (2017) 2016 Bordeaux University Prospective collected RT-PCR and 72 6
Hospital, Bordeaux, specimens from patients high-resolution
France melt analysis
Salado-Rasmussen & Jensen (2014) 2007 General practitioners, Retrospective analysis of RT-PCR and 11 3 Data for individual years
2008 private specialists, and MG-positive specimens rapid 226 81 were aggregated in the
2009 hospitals across Denmark pyrosequencing 378 135 publication. Statens Serum
2010 454 191 Institut was only laboratory
testing for macrolide resistance.
Anagrius, Loré & Jensen (2013) 2006 Department of Venerology, Retrospective analysis of RT-PCR and 18 0 Study authors provided patient
2007 Central Hospital, Falun, MG-positive specimens sequencing 53 0 numbers for each year and data
2008 Sweden 58 1 for 2012 and 2013.
2009 81 5
2010 98 14
2011 100 21
2012 71 8
2013 114 10
C
adosch
etal.(2020),PeerJ,D
O
I10.7717/peerj.8913
6/16
2013) (Table 2). Study authors provided additional information from Denmark (data
disaggregated by year) and Sweden (numbers of patients per year and unpublished data
for 2012 and 2013).
In France, we included four studies with data from 542 samples from 2003 to 2016
(Chrisment et al., 2012; Touati et al., 2014; Le Roy et al., 2016; Le Roy et al., 2017). None of
17 M. genitalium positive specimens from 2003 to 2005 contained macrolide resistance
mutations. From 2006 onwards, mutations were detected in 8% to 17% of specimens
tested in each year. In France, azithromycin was introduced for first line treatment of NGU
in the 1990s (Joly-Guillou & Lasry, 1999). For Denmark, one study reported nationwide
data from 1,008 patients with M. genitalium detected from 2006 to 2010, with 27% to
42% of specimens containing macrolide resistance mutations (Salado-Rasmussen & Jensen,
2014). In Denmark, 1g single dose azithromycin is routinely prescribed for treatment of
NGU; erythromycin was the first-line treatment before azithromycin became available. An
extended azithromycin regimen is prescribed if a M. genitalium infection was diagnosed
andNAAT for detection ofM. genitalium infections have been available since 2003 (Salado-
Rasmussen & Jensen, 2014). In Sweden, we analyzed one study with data about macrolide
resistance mutations from 408 samples obtained from 2006 to 2013 from patients at a
single clinic in Falun (Anagrius, Loré & Jensen, 2013). Macrolide resistance mutations were
first detected in a single specimen in 2008 and increased to 16% of 95 specimens in 2011.
In Sweden, doxycycline is used as first line treatment for NGU (Björnelius, Magnusson &
Jensen, 2017). Azithromycin is used only whenM. genitalium is identified as the cause, with
testing introduced in the 2000s (Anagrius, Loré & Jensen, 2013).
Mathematical modeling
The transmission model fitted the increase inM. genitalium resistance in France, Denmark
and Sweden well (Figs. 2A–2C). The model estimated treatment rates of infected people
and dates of introduction of azithromycin were: France, treatment rate of 0.04 y−1 (95% CI
[0.03–0.04] y−1), introduction of azithromycin in 1990 (95% CI [1990–2006]); Denmark,
treatment rate of 0.13 y−1 (95% CI [0.05–0.34] y−1), introduction of azithromycin in 1995
(95% CI [1990–2006]); Sweden, treatment rate of 0.14 y−1 (95% CI [0.11–0.18] y−1),
introduction of azithromycin in 2006 (95% CI [2005–2007]). A treatment rate of 0.14 y−1,
such as in Sweden, corresponds to a proportion of 1−e−0.14≈ 13% of infected individuals
that will have received treatment after one year. If treatment with single-dose azithromycin
continues at the estimated rates, macrolide-resistant M. genitalium infections will reach
25% (95% CI [9–30]%) in France, 84% (95% CI [36–98]%) in Denmark and 62% (95%
CI [48–76]%) in Sweden by 2025.
The importance of de novo resistance emergence for the early spread of macrolide-
resistantM. genitalium becomes apparent in the alternative scenarios. Lower probabilities
of de novo resistance, at the same estimated treatment rates and time points for the
introduction of azithromycin as in the main model, would have resulted in considerably
lower proportions of resistant infections (Figs. 2A, 2B and 2C). The influence of de novo
resistance emergence on the rate of resistance spread can be explained by Eq. (5) (Fig. 3).
As long as the proportion of resistant infections (p) is low, the contribution of de novo
Cadosch et al. (2020), PeerJ, DOI 10.7717/peerj.8913 7/16
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Figure 2 Maximum-likelihood fits of theM. genitalium transmissionmodel to data of azithromycin
resistance in France, Denmark and Sweden. )A–C) Increase in the proportion of drug-resistantM. gen-
italium infections. (D–F) Proportion of de novo resistance among all drug-resistantM. genitalium infec-
tions. Error bars and shaded areas correspond to the 95% confidence intervals of the data and model, re-
spectively.
Full-size DOI: 10.7717/peerj.8913/fig-2
resistance emergence (µ) to the rate at which the resistant strain replaces the susceptible
strain (1φ) is high. With increasing levels of the resistant strain, its growth advantage
diminishes and slowly approaches 1φ = τ , i.e., the spread of resistant infections will
mainly be driven by transmitted resistance. This transition is depicted in Figs. 2D, 2E and
2F. At the time of introduction of azithromycin, the proportion of de novo resistance
started at 100% and subsequently dropped in France, Denmark and Sweden. Since around
2015, the proportion of de novo resistance among all circulating macrolide-resistant M.
genitalium infections has been low in all three countries.
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Figure 3 Relative growth rate of drug-resistantM. genitalium infections as a function of the propor-
tion of resistant infections. Lines show growth rates for the best fit models for France, Denmark and
Sweden, assuming a probability of de novo resistance during treatment ofµ= 12%. Black horizontal
lines correspond to the estimated treatment rates (τ ) in each country.
Full-size DOI: 10.7717/peerj.8913/fig-3
DISCUSSION
In this study, we fitted a compartmental transmission model to time trend data about the
proportions of azithromycin-resistant M. genitalium infections in France, Denmark and
Sweden, estimated the treatment rates and the time point of introduction of azithromycin,
and projected that a majority of infections could become resistant to azithromycin in
Denmark and Sweden by 2025. We further showed that de novo resistance emergence
accelerated the early spread of macrolide-resistant M. genitalium, whereas the spread of
resistant infections is now mainly driven by transmitted resistance.
A major strength of this study is the combination of empirical data sources and
mathematical modeling. Parameters that were not available in the literature were indirectly
inferred by fitting the model to observational data. Despite its simplicity, the model
assumptions provide a coherent qualitative and quantitative explanation for the clinically
observed rapid rise of macrolide-resistantM. genitalium infections.
There are some caveats to both the observational data sources and the model. First,
owing to the small number of samples for each data point, particularly for early years,
confidence intervals for the estimates of the proportion of resistant infections are wide. In
Denmark, azithromycin has been used for a long time but data about the prevalence of drug
resistant infections were only available since 2006, which introduces more uncertainty in
the estimated point at which resistance emerged. Second, the characteristics of people tested
for M. genitalium in the three countries are not well described and differences in testing
practices between countriesmight account for some of the variation in the proportions with
macrolide resistance. An increase over time in the proportion of resistant infections was,
however, observed in all three countries. We made a number of simplifying assumptions
in our transmission model. First, we assumed that treatment rates of infected individuals
in each country were constant over time. Even though the use of azithromycin might
have changed over time, a sensitivity analysis showed that a model with a stepwise change
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in the treatment rate does not improve the model fits (results not shown). Second, we
assumed that no second-line treatments were used for resistant M. genitalium infections.
In practice, since most M. genitalium infections are asymptomatic and diagnostic testing
is still uncommon, we do not think that this simplification affected our results. Third,
our model does not include detailed population structure because the rate at which drug-
resistant bacterial strains spread in a population relative to drug-sensitive strains can often
be explained by the treatment rate, rather than the sexual network structure (Fingerhuth
et al., 2016). More complex models with different sexes, partner change rates and age
structure, would be necessary to obtain a better description of the absolute prevalence of
infections and resistance, but this was not the objective of this study.
Our study strongly suggests that, rather than resulting in ‘occasional treatment failure’
as originally believed (Jensen et al., 2008), the development of de novo resistant mutations
in about one in eight M. genitalium infections (Horner et al., 2018) is a major driver
of azithromycin resistance during the early phase of resistance spread. This finding is
supported by data from France and Sweden (Anagrius, Loré & Jensen, 2013; Chrisment et
al., 2012; Touati et al., 2014; Le Roy et al., 2016; Le Roy et al., 2017), where no macrolide
resistant mutations were detected initially, but a substantial proportion of diagnosed M.
genitalium infections were azithromycin-resistant after just a few years of azithromycin
use. The contribution of de novo resistance emergence to the spread of resistant infections
decreases as the proportion of resistant infections increases. Ourmodel-predicted estimates
of the introduction of azithromycin for the treatment of NGU were consistent with
published data describing its use in France (Joly-Guillou & Lasry, 1999) and Denmark in
the 1990s, but later introduction in Sweden (Anagrius, Loré & Jensen, 2013). Our estimated
treatment rate of infected individuals for France was lower than those for Denmark and
Sweden. The estimated rates in Denmark and Sweden are comparable to those estimated in
another epidemiological model ofM. genitalium infections in the United Kingdom (Birger
et al., 2017).
The high probability of de novo emergence of macrolide resistance mutations during
treatment of M. genitalium infections appears to differ from experiences with some
other sexually transmitted bacterial infections. A 1g dose of azithromycin might often be
insufficient to eradicate aM. genitalium infection in concert with host immune responses,
allowing for either a resistance mutation to occur in the single 23S rRNA operon during
treatment or the survival of a few pre-existing drug-resistant bacteria and the subsequent
selection of the mutants. The latter explanation is favored by the strong association with
de novo resistance and high organism load (Bissessor et al., 2015; Read et al., 2017), but
both mechanisms may play a role. The high probability of de novo resistance also has
implications for antimicrobial stewardship, as reducing blind treatment of urethritis with
single dose azithromycin could potentially recover drug susceptibility. However, this would
only be expected in the presence of a fitness cost, which has not been observed formacrolide
resistance inM. genitalium. The absence of an observable fitness cost, or of routine tests to
detect macrolide resistancemutations, has resulted in the rapid emergence and spread ofM.
genitalium resistance. In contrast, selection pressure exerted by treatment and clonal spread
are the major drivers of the spread of macrolide-resistant Neisseria gonorrhoeae, with de
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novo resistance considered to be negligible (Fingerhuth et al., 2016).N. gonorrhoeae has four
copies of the 23S rRNA gene and resistance increases with the number of mutated copies
(Unemo & Shafer, 2014). In addition, active measures are used to limit the potential for
the emergence of de novo macrolide resistance in N. gonorrhoeae, including dual therapy,
in which azithromycin is a second drug in combination with ceftriaxone. Transmitted
resistance is assumed to be responsible for most antimicrobial resistance, but a high rate of
de novo resistance emergence has been observed during treatment with various antibiotics
of infections such as Pseudomonas aeruginosa and Enterobacteriaceae (Chow et al., 1991;
Carmeli et al., 1999). In general, de novo selection of drug-resistant mutants within a single
patient occurs more often if the resistance is mediated by single-base mutations than if
acquisition of efflux pumps or other complex mechanism are needed (Unemo & Jensen,
2017). Thus, de novo resistance is distinct from the selection of drug resistance as a result
of treatment at the population level, which is more often transmitted; a situation which is
seen with most other bacterial and parasitic sexually transmitted infections.
CONCLUSIONS
Current management strategies for M. genitalium will result in a majority of infections
becoming resistant to azithromycin within the next few years, posing considerable
problems for clinical management and population level control strategies (Golden,
Workowski & Bolan, 2017). Screening and treatment of asymptomatic M. genitalium with
1g azithromycin regimens will further drive the spread of either de novo or transmitted
resistance in countries with low or high levels of resistance, with absent evidence of a
reduction in clinical morbidity (Golden, Workowski & Bolan, 2017). Treatment strategies
to maintain the use of existing antimicrobials are now being evaluated since resistance
to second line treatment with moxifloxacin is already increasing (Murray et al., 2017). In
an observational study, resistance-guided therapy for symptomatic M. genitalium, with
initial treatment with doxycycline followed by 2.5 g azithromycin over three days for
macrolide susceptible infections and sitafloxacin for resistant infections resulted in an
incidence of de novo macrolide resistance of 2.6% (95% CI [0.3–9.2]%) (Read et al., 2019).
Randomized controlled trials are now needed to evaluate different treatment algorithms
and new antimicrobials or combination therapy that might have a lower propensity for
the emergence of de novo resistance (Bradshaw, Jensen & Waites, 2017). Blind treatment
of urethritis with single dose azithromycin, which induces de novo resistance and selects
for transmitted resistance in M. genitalium, is not recommended. Clinical management
strategies for M. genitalium and other STIs should seek to limit the unnecessary use of
macrolides.
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